Founded in 1990 Biem Pharmaceuticals with headquarters in Ankara, is a privately held pharmaceutical company engaged in manufacturing, distribution and marketing of pharmaceutical and healthcare products.
The company’s strength lies in its unique offerings of a high value pharmaceutical products portfolio on the Turkish and global market, pursuing also partnerships with international leading pharmaceutical companies interested to enter on the domestic pharmaceutical market.
Our succes is an outcome of strategic focus on the pharmaceutical industry, constantly investing and promoting growth and innovation. Over the years, Biem Pharmaceuticals has extended its footprint beyond Turkey and other countries across the globe.
Our expertise lies in manufacturing and licensing of pharmaceutical products, Biem being well positioned to efficiently license, register and commercialize pharmaceutical products in Turkey, and abroad through its international partners.
Our Mission is...
to become the FIRST REMEDY for saving and improving lives through the manufacturing of high-tech, pioneering products which will satisfy the need of customers and
ONLY REMEDY able to provide innovative pharmaceutical products without pursuing high profit margins, for illnesses that affects only a small percentage of the population.
In order to achieve this mission we undertake to create value for our customers, consumers and the community.
Our Vision is…
to achieve growth in our therapeutic field with an innovative approach and steady growth, to increase the quality of our health services in all its activities, while preserving the ethical values of the health industry,
always focused to produce the best quality products, safe and efficient, by searching innovative solutions for happy and healthy lifes.
BUSINESS DEVELOPMENT
Biem Pharmaceuticals is primarily a speciality pharmaceutical marketing partner to commercialise later stage or marketed products in the territory of Turkey and select markets. We know that good partnerships are key to success. We are committed to continued and strategic growth through targeted product acquisitions, in-licensing new opportunities and forming mutually beneficial business partnerships.
At this stage, we are willing to look at all therapeutic areas with a strong focus on Biologicals, Oncology, Hematology, Ophtalmology, Radiology and Gynecology. While concentrating on speciality prescription pharmaceuticals, we will also consider acquiring generic pharmaceuticals.
